Sysmex Journal International Vol. 25 No.

1 (2015)

Introduction of Products

Overview and Features of the Automated Hematology Analyzer

Overview

XN-L Series
Yoshiko
Yoshik
oshiko AMAGUCHI*1, Tamiaki
o HAMAGUCHI amiaki KONDO*1, Rie NAKAI*1, Yasuhiro
asuhiro OCHI*1, Tomonori
omonorii OKAZAKI*2,
Tomonor
Kin a UCHIHASHI*2, Takashi
Kinya akashi MORIKAWA
ORIKA *1

*1
Scientific Affairs,
Aff
Affairs
airs,, Sysmex
Sysmex Corporation,
Cor
Corpor
poration,
ation, 1-3-2 Murotani, Nishi-ku, Kobe
Kobe 651-2241, Japan
Japan
*2
Hematology Product Engineering
Engineering Division, Sysmex
Sysmex Corporation
Cor
Corpor
poration
ation

INTRODUCTION equipped with advanced testing modalities including

In recent years, healthcare infrastructures have been
steadily constructed in emerging markets. In addition,
rapid rates of economic growth have made healthcare
information more accessible worldwide.
Thus, people have become more aware of health and
healthcare, with dramatically increasing demands for
medical care and clinical testing. In developed countries,
regional needs have diversified, such as medical cost
suppression due to the aging society and widely-
spreading personalized healthcare.
To address the dynamic healthcare terrain, we launched
the XN-Series in 2011, which improved the efficiency
and clinical values of blood cell count testing. Now we
introduce the XN-L series; compact automated
hematology analyzers that are based on XN series
functionality, operability, and clinical parameters 1-3) (Fig. 1).
These analyzers are among the world's smallest and are
reticulocyte (RET) measurement functions, a low WBC
mode, and body fluid mode. The XN-L also has the
features of conventional products including: 8 CBC
parameters, 6 WBC classifications, and trace analyte
measurement. This series includes superior service and
support systems that correspond to the Sysmex Network
Communication Systems (SNCS®) 4), contributing to safe
and efficient laboratory test environments. One analyzer
in this line, the XN-550, features automated
Rerun/Repeat/Reflex functions as an added capability.
Furthermore, this product line is already equipped to
provide future enhancements, including an optional
application to detect the infected erythrocytes in malarial
infection, which is one of the three most prevalent
infections worldwide. Sysmex is committed to advancing
hematology technologies in order to further develop the
clinical use of the automated blood cell analyzer. In this
report, XN-L series will be introduced.

Note: This article is translated and republished from Sysmex Journal Web Vol. 16 No. 1 2015.

−1−
 Sysmex Journal International Vol. 25 No. 1 (2015)

blood cell ratio (FRC%), high fluorescent lymphocyte

MAIN SPECIFICATIONS count (HFLC#), and high fluorescent lymphocyte ratio
(HFLC%).
1. Name
1) Name: Automated Hematology Analyzer XN-L series 5. Sample volume
2) Model: XN-550 (Sampler type) Sample volumes to be aspirated are 25µL and 70µL for
XN-450 (Cap-piercing type) whole blood and diluted blood/body fluid, respectively.
XN-350 (Open type) For details, see Table 2.

2. Applications 6. Throughput
These devices are hematology analyzers for blood testing Throughput is up to approx. 70 samples per hour. For
using human blood. Blood should be anticoagulated with details, see Table 3.
EDTA-2K, EDTA-3K, and EDTA-2Na for use on the
analyzers. Body fluids, such as cerebrospinal, pleural,
peritoneal, and synovial fluids, can also be measured.
7. Dimensions and weight
Dimensions (width × depth × height) and weights are
shown in Table 4.
3. Reportable parameters
There are 35 reportable whole blood parameters and 7
reportable body fluid parameters. For details, see Table
8. Reagents
1. Reagents and their measurement channels are shown in
Table 5.
4. Main research parameters
Fragmented red blood cell count (FRC#), fragmented red

Table 1 Reportable parameters

Analysis Mode Discrete Detector/Channel Parameter

WBC, RBC, HGB, HCT, MCV, MCH, MCHC, PLT
CBC RBC/PLT, HGB, WDF
RDW-SD, RDW-CV, PDW, MPV, P-LCR, PCT
Whole Blood NEUT#, LYMPH#, MONO#, EO#, BASO#, NEUT%,
mode DIFF WDF
LYMPH%, MONO%, EO%, BASO%, IG#, IG%
RET RET* RET#, RET%, IRF, LFR, MFR, HFR, RET-He, IPF#, IPF
Body Fluid mode* — RBC, WDF RBC-BF, WBC-BF, MN#, PMN#, MN%, PMN%, TC-BF

* The availability of functions depends on the system configuration.

−2−
 Sysmex Journal International Vol. 25 No. 1 (2015)

Table 2 Sample volume

XN-550/XN-450
Analysis method Specimen Test tube Cap Aspirated sample volume Required sample volume

Sampler analysis Whole Regular sample tube Close 1mL

(XN-550) blood 25µL
RBT micro collection tube Close 250µL
Close 1mL
Regular sample tube
Whole Open 300µL
blood 25µL
RBT micro collection tube Close 250µL
Micro collection tube Open 100µL
Manual analysis Regular sample tube Open 300µL
Diluted 1
blood 70µL*
Micro collection tube Open 140µL
Close 1mL
Body2 Regular sample tube
fluid* Open 70µL 300µL
Micro collection tube Open 140µL
*1: Use diluted blood prepared by diluting 20µL of whole blood1:7.
*2: The availability of body fluid analysis function depends on the system configuration.

XN-350
Analysis method Specimen Test tube Cap Aspirated sample volume
Whole blood 25µL
Manual analysis Diluted blood Regular sample tube Open
70µL
Body fluid*

* The availability of body fluid analysis function depends on the system configurations.

Table 3 Throughput

Analysis mode Discrete Throughput

CBC
Approx. 60 samples/hour (approx. 70 samples/hour*1)
CBC+DIFF
Whole blood
CBC+RET*2
2
Approx. 35 samples/hour
CBC+DIFF+RET*

2 CBC+DIFF Approx. 55 samples/hour

Low WBC* 2
CBC+DIFF+RET* Approx. 30 samples/hour
CBC
Approx. 60 samples/hour
Pre-Dilution CBC+DIFF
CBC+DIFF+RET*2 Approx. 30 samples/hour
2
Body fluid* — Approx. 30 samples/hour

*1: The throughput depends on the system configuration.

*2: The availability of functions depends on the system configurations.

−3−
 Sysmex Journal International Vol. 25 No. 1 (2015)

Table 4 Dimensions and weight

Dimensions (width × depth × height) Weight

Analyzer Approx. 450 × 660 × 450 mm Approx. 53 kg
XN-550 Monitor Approx. 267 × 205 × 240 mm Approx. 3 kg
XN-450 Analyzer Approx. 450 × 460 × 440 mm Approx. 35 kg
XN-350 Analyzer Approx. 450 × 460 × 510 mm Approx. 35 kg

Table 5 Reagents

Channel Reagent type Product name

Diluent (concentrated reagent) CELLPACK DST*1
Each channel
Diluent CELLPACK DCL
HGB channel Hemolytic agent SULFOLYSER
Hemolytic agent Lysercell WDF
WDF channel
Stain solution Fluorocell WDF
2 Diluent CELLPACK DFL
RET channel*
Stain solution Fluorocell RET
*1: Use of CELLPACK DST depends on the system configuration.
*2: The availability of functions depends on the system configurations.

In principle, blood cells are lysed with sodium lauryl

TECHNOLOGY
1. Measurement principles
1) Flow cytometry
The XN-L uses reliable flow cytometry technology using
a semiconductor laser which inherits the technology of
XN-Series 4) to provide high-performance measurements
in a compact design. Blood cells are treated with specific
reagents, and are expanded on multi-dimensional
scattergrams through the conversion of forward scattered
-, side scattered-, and side fluorescent light into electrical
impulses. Each scattergram is analyzed using original
technologies to calculate measurements (Table 6). The
low WBC and body fluid modes improve accuracy by
increasing the amount of blood cells counted. Also,
reticulocyte hemoglobin equivalents (RET-He) and
immature platelet fraction (IPF) are determined.
2) Hydro dynamic focusing method (direct current:
DC detection method) 5)
Red blood cell and platelet counts are determined using
Hydro dynamic focusing method. In principle, the
coincidence and recount of blood cells are minimized,
facilitating accurate measurements of blood counts and
volumes.
3) SLS hemoglobin method 6)
Hemoglobin concentrations are determined by the SLS
hemoglobin method without using toxin or special
oxidizing agents.
sulfate (SLS), followed by colorimetric measurements.
This method is suitable for automation.
2. Body fluid mode 1)
The devices are equipped with a body fluid mode.
Without sample pretreatment, white blood cell (WBC-
BF) and red blood cell (RBC-BF) counts as well as
mononuclear (MN#, MN%) and polymorphonuclear
(PMN#, PMN%) leukocyte ratios can be determined and
reported. The measurement accuracy is improved by
increasing the particle counts approximately tenfold in
white blood cells and threefold in red blood cells, when
compared to the whole blood mode.
3. Low WBC mode 2,3)
The devices are equipped with a low WBC mode,
facilitating the accurate determination of low WBC
counts. In principle, sample volume to be measured is
doubled, as compared with the whole blood mode,
thereby improving the measurement accuracy.
4. Automated dispensing function of diluent
The devices dispense 120µL of CELLPACK DCL into an
empty micro collection tube. Subsequently, diluted blood
prepared with 20µL of sample can be measured. This
facilitates the measurement of small blood volumes
which is especially useful for patient populations
including geriatric and infant.

−4−
 Sysmex Journal International Vol. 25 No. 1 (2015)
Table 6 Measurement channels and detection parameters
Channel Detection parameters
White blood cell count
WDF
WBC 6 differentiation for white blood cell
RET* Reticulocyte
* The availability of functions depends on your system configurations.
BASIC PERFORMANCE
1. Within-run reproducibility
1) Whole blood mode
Within-run reproducibility was demonstrated using three
blood samples from healthy volunteers each with 10-
consecutive measurements in whole blood mode. Results
are shown in Table 7. The CV values of main parameters
were WBC : 1.3 - 2.0%, RBC : 0.3 - 0.7%, HGB : 0.3 -
0.5%, HCT : 0.2 - 0.8%, PLT-I : 2.0 - 2.2%, and PLT-O :
0.8 - 2.1%.
2) Body fluid mode
Within-run reproducibility in body fluid mode was
demonstrated by preparing samples in three different
concentrations using quality control material (XN
CHECK BF) and measuring each in 10-consecutive runs.
This data is shown in Table 8. The CV values of main
parameters were WBC-BF : 5.6 - 9.3%, RBC-BF : 2.4 -
10.6% , and TC-BF# : 5.6 - 9.3%.
2. Correlation
1) Whole blood mode
A correlation between XN-550 (XN-L series) and
XN-1000 (XN-Series) in the whole blood mode using
patient blood samples (EDTA-2K added, N = 106, provided
by the Improvement for Measurement and Diagnostic
Technique Project at Department of Laboratory Tests,
University of Tsukuba Hospital, Japan) is shown in Fig. 2.
The correlation coefficients (r) of main parameters were
WBC : 0.9974, RBC : 0.9984, HGB : 0.9987, HCT : 0.9976,
and PLT : 0.9982.
−5−
Detection parameters
Forward scattered light - side scattered light (CBC)
Side scattered light - side fluorescence light (CBC + DIFF)
Side fluorescence light - forward scattered light
2) Body fluid mode
A correlation between XN-550 (XN-L series) and XN-1000
(XN-Series) using 20 celomic fluid, 12 cerebrospinal fluid,
and 23 peritoneal dialysate in the body fluid mode is shown
in Fig. 3. The correlation coefficients (r) of each parameter
was WBC-BF : 0.9994, RBC-BF : 0.9995, and TC-BF# :
0.9993.
3. Minimum detection sensitivity
1) Whole blood mode
Minimum sensitivities (limit of blank : LoB, limit of
detection : LoD, and limit of quantitation : LoQ) in
measuring a quality control material (e-CHECK) for
which the concentration has been adjusted and
CELLPACK DCL in the whole blood mode are shown in
Table 9. The minimum detection sensitivities of main
parameters were WBC (CBC + DIFF mode) : 0.01 ×
109/L, RBC : 0.00 × 1012/L, and PLT : 1 × 109/L.
2) Low WBC mode
Minimum sensitivities (LoB, LoD, and LoQ) in
measuring a quality control material (e-CHECK) for
which the concentration has been adjusted and
CELLPACK DCL in the low WBC mode are shown in
Table 10. The minimum detection sensitivities of main
parameters were WBC : 0.01 × 109/L, RBC : 0.00 ×
1012/L, and PLT : 1 × 109/L.
3) Body fluid mode
Minimum sensitivities (LoB, LoD, and LoQ) in
measuring a quality control material (e-CHECK) for
which the concentration has been adjusted and
CELLPACK DCL in the body fluid mode are shown in
Table 11. The minimum detection sensitivities of main
parameters were WBC-BF : 0.001 × 109/L, RBC-BF :
0.000 × 1012/L, and TC-BF# : 0.001 × 109/L.
 Sysmex Journal International Vol. 25 No. 1 (2015)

Table 7 Within-run reproducibility of the whole blood mode

WBC-C*1 WBC-D*2 RBC HGB HCT MCV MCH MCHC PLT-I PLT-O
(109/L ) (109/L ) (1012/L ) (g/L ) (L/L ) (fL) (pg) (g/L ) (109/L ) (109/L )
AVE. 6.948 6.915 5.206 162.7 0.5020 96.43 31.25 324.1 312.1 298.2
1 SD 0.140 0.138 0.014 0.7 0.0012 0.07 0.16 1.9 6.2 2.3
CV 2.0% 2.0% 0.3% 0.4% 0.2% 0.1% 0.5% 0.6% 2.0% 0.8%
AVE. 9.091 9.012 5.014 148.0 0.4682 93.38 29.52 316.0 259.6 250.6
2 SD 0.117 0.114 0.035 0.7 0.0035 0.15 0.23 2.6 5.6 4.1
CV 1.3% 1.3% 0.7% 0.5% 0.8% 0.2% 0.8% 0.8% 2.2% 1.6%
AVE. 3.661 3.638 4.783 154.2 0.4672 97.68 32.25 330.1 174.5 170.6
3 SD 0.046 0.048 0.030 0.4 0.0030 0.11 0.22 2.1 3.8 3.7
CV 1.3% 1.3% 0.6% 0.3% 0.7% 0.1% 0.7% 0.6% 2.2% 2.1%

NEUT% LYMPH% MONO% EO% BASO% RET% RET# RET-He

(%) (%) (%) (%) (%) (%) (109/L ) (pg)
AVE. 56.59 34.51 5.48 2.89 0.53 2.437 126.87 33.11
1 SD 0.82 0.91 0.22 0.22 0.14 0.055 2.74 0.06
CV 1.5% 2.6% 4.0% 7.6% 26.8% 2.3% 2.2% 0.2%
AVE. 74.78 14.19 8.56 2.07 0.40 1.966 98.57 32.60
2 SD 0.51 0.52 0.45 0.17 0.09 0.053 2.67 0.09
CV 0.7% 3.6% 5.2% 8.2% 23.6% 2.7% 2.7% 0.3%
AVE. 44.86 46.58 6.49 1.50 0.57 1.086 51.94 33.96
3 SD 0.69 0.78 0.40 0.29 0.15 0.061 2.79 0.19
CV 1.5% 1.7% 6.1% 19.4% 26.2% 5.6% 5.4% 0.6%

*1 WBC-C: The total white blood cell count measured from the forward scattered light and side scattered light of WDF channel (CBC mode).
*2 WBC-D: The white blood cell count measured from the WDF channel (CBC + DIFF mode).

Table 8 Within-run reproducibility of the body fluid mode

WBC-BF RBC-BF TC-BF

(109/L ) (1012/L ) (109/L )
AVE. 0.0104 0.0066 0.0104
SD 0.0008 0.0007 0.0008
1 CV 8.1% 10.6% 8.1%
MAX 0.012 0.008 0.012
MIN 0.009 0.006 0.009
AVE. 0.0211 0.0118 0.0211
SD 0.0020 0.0006 0.0020
2 CV 9.3% 5.4% 9.3%
MAX 0.025 0.013 0.025
MIN 0.018 0.011 0.018
AVE. 0.0464 0.0268 0.0464
SD 0.0026 0.0006 0.0026
3 CV 5.6% 2.4% 5.6%
MAX 0.050 0.028 0.050
MIN 0.043 0.026 0.043

−6−
 Sysmex Journal International Vol. 25 No. 1 (2015)

WBC (109/L ) RBC (1012/L ) HGB (g/L )

25 y = 1.0094x - 0.1048 8.0 y = 0.9987 x + 0.03 200 y = 0.9878 x + 0.7966

r = 0.9974 r = 0.998 4 r = 0.9987
20 n = 106 n = 106 n = 106
6.0 150

15
XN-550

XN-550

XN-550
4.0 100
10

2.0 50
5

0 0.0 0
0 5 10 15 20 25 0.0 2.0 4.0 6.0 8.0 0 50 100 150 200
XN-1000 XN-1000 XN-1000

HCT (L/L ) MCV (fL) MCH (pg)

0.6 y = 0.9793x + 0.0076 140 y = 1.0375x - 3.9786 45 y = 0.9695 x + 0.0565

r = 0.9976 r = 0.9946 r = 0.9900
n = 106 n = 106 n = 106
120
0.4 35
XN-550
XN-550

XN-550
100

0.2 25
80

0.0 60 15
0.0 0.2 0.4 0.6 60 80 100 120 140 15 25 35 45
XN-1000 XN-1000 XN-1000

PLT (10 9/L)

1,000 y = 0.9627 x + 0.0286

r = 0.9982
800 n = 106
XN-550

600
XN-550

400

200

0
0 200 400 600 800 1,000
XN-1000 XN-1000

Fig. 2-1 Correlations among CBC 8 parameters

−7−
 Sysmex Journal International Vol. 25 No. 1 (2015)

RDW-SD (fL) RDW-CV (%) PDW (fL)

80 y = 0.9529 x + 1.0553 30 y = 0.9673 x + 0.3215 20 y = 0.8543 x + 1.4693
r = 0.9910 r = 0.9976 r = 0.9428
70 n = 106 n = 106 n = 105
25
15
60
XN-550

XN-550

XN-550
20
50
10
15
40

30 10 5
30 40 50 60 70 80 10 15 20 25 30 5 10 15 20
XN-1000 XN-1000 XN-1000

MPV (fL) P-LCR (%) PCT (% )

16 y = 0.9526 x + 0.3205 60 y = 0.9265 x + 0.4405 1.0 y = 0.9613x - 0.0032
r = 0.9577 r = 0.9766 r = 0.9949
14 n = 105 n = 105 0.8 n = 105
40
12 0.6
XN-550

XN-550

XN-550
10 0.4
20
8 0.2

6 0 0.0
6 8 10 12 14 16 0 20 40 60 0.0 0.2 0.4 0.6 0.8 1.0
XN-1000 XN-1000 XN-1000

Fig. 2-2 Correlations among analytical parameters

NEUT% (%) LYMPH% (%) MONO% (%)

120 y = 0.9764x + 1.2967 80 y = 0.984 x + 0.5881 40 y = 0.9651x + 0.2871
r = 0.9959 r = 0.9952 r = 0.9774
100 n = 106 n = 106 n = 106
60 30
80
XN-550

XN-550

XN-550

60 40 20

40
20 10
20

0 0 0
0 20 40 60 80 100 120 0 20 40 60 80 0 10 20 30 40
XN-1000 XN-1000 XN-1000

EO% (%) BASO% (%) IG% (%)

30 y = 0.9604 x + 0.0875 3.0 y = 0.6356 x + 0.2632 15 y = 0.852 x - 0.1624
r = 0.9933 r = 0.671 7 r = 0.985 1
25 n = 106 2.5 n = 106 n = 106

20 2.0 10
XN-550

XN-550

XN-550

15 1.5

10 1.0 5

5 0.5

0 0.0 0
0 5 10 15 20 25 30 0.0 0.5 1.0 1.5 2.0 2.5 3.0 0 5 10 15
XN-1000 XN-1000 XN-1000

Fig. 2-3 Correlations among WDF channel parameters

−8−
 Sysmex Journal International Vol. 25 No. 1 (2015)

RET# (10 9/L) RET% (%) IRF (%)

250 y = 1.0176x - 0.6837 15 y = 1.037x - 0.5976 60 y = 1.0754 x + 0.6081
r = 0.9885 r = 0.9961 r = 0.9768
200 n = 106 12 n = 106 50 n = 106
40
150 9
XN-550

XN-550

XN-550
30
100 6
20
50 3 10

0 0 0
0 50 100 150 200 250 0 3 6 9 12 15 0 10 20 30 40 50 60
XN-1000 XN-1000 XN-1000

LFR (%) MFR (%) HFR (% )

120 y = 1.0754x - 8.1507 30 y = 0.9835 x + 1.1739 30 y = 1.1474 x + 0.1421

r = 0.9768 r = 0.9354 r = 0.9833
n = 106 25 n = 106 n = 106
100
20 20

XN-550
XN-550

XN-550

80 15

10 10
60
5

40 0 0
40 60 80 100 120 0 5 10 15 20 25 30 0 10 20 30
XN-1000 XN-1000 XN-1000

RET-He (pg) IPF (%)

y = 1.2209 x + 0.7131
50 20 r = 0.7779
y = 0.9794x + 0.3284
n = 106
r = 0.9908
n = 106
40 15
XN-550

XN-550

30 10

20 5

10 0
10 20 30 40 50 0 5 10 15 20
XN-1000 XN-1000

RBC-O (10 12/L) PLT-O (10 9/L)

y = 1.0455x + 2.7218
8 1,200 r = 0.9972
y = 1.0005 x + 0.0092
r = 0.9963 n = 106
1,000
n = 106
6
800
XN-550

XN-550

4 600

400
2
200

0 0
0 2 4 6 8 0 200 400 600 800 1,000 1,200
XN-1000 XN-1000

Fig. 2-4 Correlations among RET channel parameters

−9−
 Sysmex Journal International Vol. 25 No. 1 (2015)

WBC-BF (109/L ) RBC-BF (1012/L ) TC-BF# (109/L )

10 y = 1.0722x - 0.0059 0.10 y = 0.9591x+0.00004 10 y = 1.067x - 0.0081

r = 0.9994 r = 0.9995 r = 0.9993
8 n = 55 0.08 n = 55 8 n = 55

6 0.06 6
XN-550

XN-550

XN-550
4 0.04 4

2 0.02 2

0 0.00 0
0 2 4 6 8 10 0.00 0.02 0.04 0.06 0.08 0.10 0 2 4 6 8 10
XN-1000 XN-1000 XN-1000

MN# (109/L ) PMN# (109/L )

y = 1.0779x - 0.0028
10 y = 1.0635x - 0.0001 10 r = 0.9977
r = 0.9997 n = 55
8 n = 55 8

6 6
XN-550

XN-550

4 4

2 2

0 0
0 2 4 6 8 10 0 2 4 6 8 10
XN-1000 XN-1000

MN% (% )* PMN% (% )*
y = 0.7236 x + 21.398
r = 0.7825 y = 0.9088x + 2.6322
100 100
n = 44 r = 0.9000
n = 44
80 80

60 60
XN-550

XN-550

40 40

20 20

0 0
0 20 40 60 80 100 0 20 40 60 80 100
XN-1000 XN-1000

* MN% and PMN% parameters: N= 44, as samples not satisfying the LoQ (WBC-BF < 0.003 × 109/L) were excluded.

Fig. 3 Correlations among body fluid parameters

− 10 −
 Sysmex Journal International Vol. 25 No. 1 (2015)

Table 9 Minimum detection sensitivity of the whole blood mode

WBC-C WBC-D RBC HGB HCT PLT-I PLT-O

(109/L ) (109/L ) (1012/L ) (g/L ) (L/L ) (109/L ) (109/L )
LoB 0.01 0.00 0.00 0 0.000 0 0
LoD 0.02 0.01 0.00 0 0.000 1 1
LoQ 0.03 0.02 0.00 0 0.000 2 2

Table 10 Minimum detection sensitivity of the low WBC mode

WBC-C RBC HGB HCT PLT-I PLT-O

(109/L ) (1012/L ) (g/L ) (L/L ) (109/L ) (109/L )
LoB 0.00 0.00 0 0.000 0 0
LoD 0.01 0.00 0 0.000 1 1
LoQ 0.01 0.00 0 0.000 2 2

Table 11 Minimum detection sensitivity of the body fluid mode

WBC-BF RBC-BF TC-BF#

(109/L ) (1012/L ) (109/L )
LoB 0.000 0.000 0.000
LoD 0.001 0.000 0.001
LoQ 0.002 0.001 0.002

screening information for cytology to detect tumor cells9).

FEATURES
In spite of its small size, XN-L series can provide various
healthcare information (RET, RET-He, and body fluid
parameters) which may assist clinicians in diagnostic
decisions.
RET-He reflects the hemoglobin levels in reticulocytes
and is a sensitive indicator of iron utilization in
erythropoiesis. Thus, it should facilitate the treatment and
management of anemia in patients with chronic kidney
disease 7) and improve the safety of autologous blood
donation 8).
The XN-L series allows the measurements of white blood
cells, red blood cells, mononuclear cells, and
polymorphonuclear leukocytes in the body fluid mode.
Thus, it allows users to make rapid and objective reports
of measurements from emergency tests at non-business
hours, as well as from daily practices. This feature should
be particularly useful in the diagnosis of central nervous
system infection. In addition, it may be utilized as
The XN-L series is also equipped with a PLT-I/PLT-O
switching function. The impedance platelet count (PLT-I)
comes from the hydro dynamic focusing method, while
the optical platelet count (PLT-O) is measured in the
RET channel using flow cytometry. Usually, the PLT-I is
employed as platelet count, while the PLT-O is
automatically reported as platelet count for samples with
abnormal platelet particle size distributions, such as those
with fragmented red blood cells 10).
This function facilitates reporting of more reliable
platelet counts.
In addition, with customers' analytical devices and our
customer support centers connected on-line, the XN-L
series provides real-time quality control and fault
monitoring/repair support on the outsourcing basis, and
SNCS® service function providing information on the
web 4, 11). More than 24,000 devices are connected on the
web around the world, facilitating reporting of accurate
measurements and maintenance of devices.

− 11 −
 Sysmex Journal International Vol. 25 No. 1 (2015)
ADDITIONAL VALUES
Like XN-Series, the XN-L series also provides
parameters such as immature granulocyte (IG) count and
IPF.
Studies have shown that IG may facilitate the detection
of inflammatory reaction easier and quicker when
combined with existing parameters, such as C-reactive
protein and erythrocyte sedimentation rate 12).
Reticulated platelet counts reflect the platelet production
ability of the bone marrow. The XN-L series allows
automatic measurement of its related parameter IPF. IPF
has been reported useful in predicting platelet recovery
time after chemotherapy or hematopoietic stem cell
transplantation 13) and may aid clinicians in the
differential diagnosis of thrombocytopenic disorders,
such as immunological thrombocytopenia (e.g.,
idiopathic thrombocytopenic purpura) 14).
CONCLUSIONS
This report introduced the newly released Automated
Hematology Analyzer XN-L series. Using many of the
same technologies as the higher throughput XN-series,
these compact analyzers contribute to accurate
measurement techniques and testing efficiency and can
be customized to fit the unique needs of each customer.
In addition, it employs systems developable onward so
that the wide spread usage of hematology analyzers in
clinical practice can be expected in future.
References
1) Fleming C et al. Validation of the body fluid module on the new
Sysmex XN-1000 for counting blood cells in cerebrospinal fluid
and other body fluids. Clin Chem Lab Med. 2012;50(10):1791-8.
2) Briggs C et al. Performance evaluation of the Sysmex haematology
XN modular system. J Clin Pathol. 2012 Nov;65(11): 1024-30.
− 12 −
3) Seo JY et al. Performance evaluation of the new hematology
analyzer Sysmex XN-series. Int J Lab Hematol. 2015; 37(2): 155-
64.
4) Ochi Y et al. Overview of the Automated Hematology Analyzer
XN-Series. Sysmex Journal 2011; 34(2): 1-16. (Japanese).
5) Fujimoto K. Principles of measurement in hematology analyzers
manufactured by Sysmex Corporation. Sysmex Journal
International. 1999; 9(1): 31-44.
6) Oshiro I et al. New method for hemoglobin determination by using
sodium lauryl sulfate (SLS). Clinical biochemistry. 1982; 15(2):
83-88.
7) Miwa N et al. Usefulness of measuring reticulocyte hemoglobin
equivalent in the management of haemodialysis patients with iron
deficiency. Int J Lab Hematol. 2010; 32(2):248-55.
8) Shibayama M et al. Usefulness of reticulocyte hemoglobin
equivalent for the safety of pre-operative autologous blood
donation. Rinsho Byori. 2011; 59(6): 565-70. (Japanese).
9) Zimmermann M et al. Cellular origin and diagnostic significance
of high-fluorescent cells in cerebrospinal fluid detected by the XE-
5000 hematology analyzer. International Journal of Laboratory
Hematology. 2013; 35(6): 580-588.
10) Inoue H. Overview of Automated Hematology Analyzer XE-2100.
Sysmex Journal International. 1999; 9(1): 58-64.
11) Hayashi M. How the IT Revolution is affecting trends in Clinical
Testing. Sysmex Journal International. 2000; 10(1): 1-2.
12) Briggs C et al. Evaluation of immature granulocyte counts by the
XE-IG master: upgraded software for the XE-2100 automated
hematology analyzer. Lab. Hematol. 2003; 9(3): 117-24.
13) Yamaoka G et al. The immature platelet fraction is a useful marker
for predicting the timing of platelet recovery in patients with
cancer after chemotherapy and hematopoietic stem cell
transplantation. Int J Lab Hematol. 2010; 32(6 Pt 1): 208-16.
14) Sakuragi M et al. Clinical significance of IPF% or RP%
measurement in distinguishing primary immune thrombocytopenia
from aplastic thrombocytopenic disorders. Int J Lab Hematol.
2015; 101(4): 369-75.